SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-23-041378
Filing Date
2023-08-10
Accepted
2023-08-10 16:25:58
Documents
59
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q antx-20230630.htm   iXBRL 10-Q 2893830
2 EX-31.1 antx-ex31_1.htm EX-31.1 20953
3 EX-31.2 antx-ex31_2.htm EX-31.2 21371
4 EX-32.1 antx-ex32_1.htm EX-32.1 10855
5 EX-32.2 antx-ex32_2.htm EX-32.2 10589
  Complete submission text file 0000950170-23-041378.txt   8478091

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT antx-20230630.xsd EX-101.SCH 48230
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT antx-20230630_lab.xml EX-101.LAB 389390
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT antx-20230630_cal.xml EX-101.CAL 31977
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT antx-20230630_def.xml EX-101.DEF 167040
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT antx-20230630_pre.xml EX-101.PRE 285910
53 EXTRACTED XBRL INSTANCE DOCUMENT antx-20230630_htm.xml XML 1335763
Mailing Address 1800 EL CAMINO REAL, SUITE D MENLO PARK CA 94027
Business Address 1800 EL CAMINO REAL, SUITE D MENLO PARK CA 94027 (650) 331-9090
AN2 Therapeutics, Inc. (Filer) CIK: 0001880438 (see all company filings)

IRS No.: 820606654 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41331 | Film No.: 231159938
SIC: 2834 Pharmaceutical Preparations